Form 4: Xenon Pharmaceuticals Director Reports Stock Transaction
Insider Transaction (Form 4)
Dawn Svoronos, a Director of Xenon Pharmaceuticals Inc., reported multiple transactions in common stock on September 1, 2026.
Summary
- Option exercise/conversion: acquired 5,144 Common Shares at $8.15 ($41,924) on September 1, 2026; holds 31,373 after (Direct).
- Option exercise/conversion: disposed of 5,144 Stock Option (Right to Buy) on September 1, 2026 (Direct).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.
Insider Transactions
Dawn Svoronos — Director
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-09-01 | Option exercise/conversion | Common Shares | 5,144 | $8 | $41.9K | 31,373 |
| 2026-09-01 | Option exercise/conversion | Stock Option (Right to Buy) | 5,144 | — | — | 0 |
Key Dates
| Date | Description |
|---|---|
| 2026-09-01 | Option exercise/conversion (5,144 shares) |
| 2026-09-01 | Option exercise/conversion (5,144 shares) |
Keywords
insider transaction, Form 4, XENE, Xenon Pharmaceuticals Inc., neutral, Dawn Svoronos
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.